Evidence map›Paper›PMID 39438000›Full record

ArticleCancer research and treatment2025

Association between Tumor Size at the Time of Disease Progression and Survival Outcomes.

Chi Hoon Maeng, Bum Jun Kim, Myung-Ju Ahn, In Sil Choi, Dae Young Zang, Bo-Hyung Kim, Minji Kwon, Dae Seog Heo, Bhumsuk Keam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chi Hoon MaengDepartment of Medical Oncology and Hematology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
Bum Jun KimDivision of Hematology-Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Myung-Ju AhnDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
In Sil ChoiDepartment of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Dae Young ZangDivision of Hematology-Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Bo-Hyung KimDepartment of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Korea.
Minji KwonDepartment of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Korea.
Dae Seog HeoDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Funding

PROVIDE RABBITS, RATS MICE, HAMSTERS GERBILS, GUINEA PIGS27307C0012 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$1.0M
Korean Cancer Study GroupMinistry of Health and Welfare HA22C0012National Cancer CenterNIEHS NIH HHS 27307C0012
6 · The paper itself

Abstract

purposeThis study evaluates the prognostic significance of tumor size at disease progression (PD) and depth of response (DOR) in cancer patients. MATERIALS AND

methodsWe performed post hoc analysis using data from six prospective clinical trials conducted by the Korean Cancer Study Group. Patients with tumor size at PD was categorized into 'Mild PD' and 'Significant PD' based on the cutoff values of relative change from baseline using maximally selected rank statistics. The overall survival (OS) and progression-free survival (PFS) were compared between PD and DOR categories.

resultsAmong the 194 evaluable patients, 130 experienced PD. A 35.48% decrease from baseline in tumor size at PD was chosen for the cutoff between mild and significant PD for OS (mild PD: tumor size from the baseline ≤ -35.48%; significant PD > -35.48%). The mild PD had superior OS compared to the significant PD (25.8 vs. 12.8 months; Hazard ratio [HR] 0.47, 95% CI 0.266-0.843, p=0.009). When using an exploratory cutoff based on whether the tumor size was below vs. exceeded from the baseline (mild PD: tumor size from the baseline ≤ 0%; significant PD > 0%), OS remained significantly longer in the mild PD (17.1 vs. 11.8 months; HR 0.60, 95% CI 0.392-0.932, p=0.021). The greatest DOR was associated with the longest OS and PFS (p<0.001 for both).

conclusionTumor size at PD and DOR were significant prognostic factors for progressive disease. Maintaining a sufficiently reduced tumor size even during PD was associated with better survival outcomes.

Indexed as

NeoplasmsTumor BurdenAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalProspective StudiesDisease progressionNeoplasms/drug therapyPrognosisResponse Evaluation Criteria in Solid TumorsSurvival analysisTreatment outcomeTumor size

Identifiers

PMID39438000
PMCPMC12016818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.